|
03 Jun 2025 |
Global Health
|
Consensus Share Price Target
|
1217.10 |
1273.87 |
- |
4.66 |
buy
|
|
|
|
|
17 May 2025
|
Global Health
|
Emkay
|
1217.10
|
1175.00
|
1201.10
(1.33%)
|
Target met |
Sell
|
|
|
Global Health (Medanta)’s Q4FY25 print was in line with street/our estimates. The Developing portfolio continued its healthy trajectory, as OBD grew 36% YoY (favorable base) while ARPOBs fell 7% on higher contribution of schemebased patients in both—Lucknow and Patna units.
|
|
24 Mar 2025
|
Global Health
|
Axis Direct
|
1217.10
|
1390.00
|
1230.65
(-1.10%)
|
14.21 |
Buy
|
|
|
We recommend a BUY on the stock with a target price of Rs 1,390/share, implying an upside of 10% from the CMP
|
|
06 Feb 2025
|
Global Health
|
Axis Direct
|
1217.10
|
1270.00
|
1168.50
(4.16%)
|
Target met |
Buy
|
|
|
We maintain a BUY rating on Medanta
|
|
30 Nov 2024
|
Global Health
|
Axis Direct
|
1217.10
|
1200.00
|
1075.15
(13.20%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a target price of Rs 1200/share, implying an upside of 11% from the CMP.
|
|
18 Nov 2024
|
Global Health
|
Axis Direct
|
1217.10
|
1200.00
|
1080.90
(12.60%)
|
Target met |
Buy
|
|
|
The target price is set at Rs 1,200/share, representing an upside potential of 12% from the CMP. This valuation is based on a multiple of 25x EV/EBITDA for FY26E.
|
|
06 Sep 2024
|
Global Health
|
Motilal Oswal
|
1217.10
|
1380.00
|
1110.95
(9.55%)
|
13.38 |
Buy
|
|
|
With a strong presence in the north/central region of India, MEDANTA has ~3,440 bed capacity as of 1QFY25. It is ramping up its capacity/capabilities in these regions, especially in Lucknow/Patna/Noida, with plans to add ~500 beds.
|
|
12 Aug 2024
|
Global Health
|
Axis Direct
|
1217.10
|
1245.00
|
1081.75
(12.51%)
|
Target met |
Buy
|
|
|
We have BUY on the stock
|
|
03 Jun 2024
|
Global Health
|
Axis Direct
|
1217.10
|
1475.00
|
1166.25
(4.36%)
|
|
Buy
|
|
|
We initiate coverage on Global Health Ltd with a BUY recommendation and DCF-based Target Price (TP) of Rs 1,475/share
|
|
04 Jan 2024
|
Global Health
|
Motilal Oswal
|
1217.10
|
1170.00
|
990.25
(22.91%)
|
Target met |
Buy
|
|
|
|
|
12 Nov 2023
|
Global Health
|
Motilal Oswal
|
1217.10
|
1050.00
|
950.15
(28.10%)
|
Target met |
Buy
|
|
|
|
|
28 Sep 2023
|
Global Health
|
Motilal Oswal
|
1217.10
|
840.00
|
715.10
(70.20%)
|
Target met |
Buy
|
|
|
|
|
29 May 2023
|
Global Health
|
Axis Direct
|
1217.10
|
325.00
|
292.00
(316.82%)
|
Target met |
Buy
|
|
|
We have BUY recommendation with TP Rs 325/share
|
|
04 Nov 2022
|
Global Health
|
SBI Securities
|
1217.10
|
|
|
|
IPO Subscribe
|
|
|
|
|
03 Nov 2022
|
Global Health
|
Hem Securities
|
1217.10
|
|
|
|
IPO Subscribe
|
|
|
|
|
03 Nov 2022
|
Global Health
|
Chola Wealth Direct
|
1217.10
|
|
|
|
IPO Subscribe
|
|
|
|
|
03 Nov 2022
|
Global Health
|
ICICI Direct
|
1217.10
|
|
|
|
IPO Subscribe
|
|
|
|
|
02 Nov 2022
|
Global Health
|
HDFC Securities
|
1217.10
|
|
|
|
IPO Note
|
|
|
Issue Snapshot: Issue Open: Nov 03 Nov 07, 2022 Price Band: Rs. 319 336 *Issue Size: Rs 2205.57 cr (Fresh issue of Rs. 500 cr + offer for sale of Rs 50,761,000 eq sh) Reservation for: QIB upto 50% eq sh Non Institutional atleast 15% eq sh ((including 1/3rd for applications between Rs.2 lakhs to Rs.10 lakhs)) Retail atleast 35% eq sh Face Value: Rs 2 Book value: Rs 66.17 (June 30, 2022) Bid size: - 44 equity shares and in multiples thereof 100% Book built Issue ipo-note-global-health-limited
|
|
02 Nov 2022
|
Global Health
|
Angel Broking
|
1217.10
|
|
|
|
IPO Note
|
|
|
Incorporated in 2004, Global Health Limited (GHL) is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. GHL has a network of 5
|
|
02 Nov 2022
|
Global Health
|
AUM Capital
|
1217.10
|
|
|
|
IPO Subscribe
|
|
|
|
|
02 Nov 2022
|
Global Health
|
Ventura
|
1217.10
|
|
|
|
IPO Subscribe
|
|
|
|